Search - tctmd.com

Displaying 481 - 500 of 1898

Sort: Relevancy | Date

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? For Limb Ischemia There Are Knowns and Unknowns!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Amit Patel

October 15, 2015

$Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!$

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry

October 15, 2015

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? Yes, Mesenchymal Cells Are Ready to Be Tested for Prevention and Treatment of Chronic Ischemic and Nonischemic Heart Failure!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Emerson C. Perin

October 15, 2015

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? Yes, in STEMI Bone Marrow Mononuclear Fraction Is Ready, and Other Options Are Coming!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Ricardo Sanz-Ruiz

October 15, 2015

News Industry News

Study Shows Initial Aortic Valve Replacement In Asymptomatic Patients With Severe Aortic Stenosis May be Viable Treatment Option

October 15, 2015

News Industry News

Edwards SAPIEN 3 Valve Demonstrates High Survival And Low Stroke Rate At 1 Year

October 15, 2015

Presentation TCT 2015

CE-Approved or EU Studies: JenaValve Technology Review and Clinical Update (JUPITER Trials)

Presenter: Martin B. Leon, Nicolo Piazza, Hendrik Treede

October 14, 2015

Presentation TCT 2015

Reversal Agents for Factor Xa Inhibitors

Presenter: Lisa K. Jennings, Matthew T. Roe

October 14, 2015

Presentation TCT 2015

Rivaroxaban: Analysis of Efficacy, Safety, and Special Considerations

Presenter: Lisa K. Jennings, Matthew T. Roe, Manesh R. Patel

October 14, 2015

Presentation TCT 2015

Apixaban: Analysis of Efficacy, Safety, and Special Considerations

Presenter: Lisa K. Jennings, Matthew T. Roe

October 14, 2015

Presentation TCT 2015

Dabigatran: Analysis of Efficacy, Safety, and Special Considerations (Including Reversal Agents)

Presenter: Lisa K. Jennings, Matthew T. Roe, Pascal Vranckx

October 14, 2015

News Industry News

Randomized Trial Of Diabetic Patients In India Finds Paclitaxel-Eluting Stents Failed To Meet Non-Inferiority Compared To Everolimus-Eluting Stents

October 14, 2015

News Industry News

Polymer-Free Drug-Coated vs. Bare-Metal Coronary Stents In High Bleeding Risk Patients With One Month DAPT

October 14, 2015

News Conference News TCT 2015

PFO Closure Still Attracts Controversy

Yael L. Maxwell

October 14, 2015

News Conference News TCT 2015

MISTRAL-C: Cerebral Protection in TAVR May Reduce New Lesions

October 14, 2015

News Conference News TCT 2015

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Yael L. Maxwell

October 14, 2015

News Conference News TCT 2015

ISAR-DESIRE 4: Scoring Balloon Predilation Effective at 1 Year in Patients With DES Restenosis

October 14, 2015

News Industry News

First US Multi-center Study Finds Unprotected TAVR Procedures Produce New Brain Lesions in Nearly All Cases

October 14, 2015

News Industry News

Drug-Coated Balloon Shown To Be Superior To Conventional Angioplasty In Treating Superficial Femoral Artery Disease After Two Years

October 14, 2015

Presentation TCT 2015

Big Data: Opportunities and Challenges 4 Academia Perspectives

Presenter: Roxana Mehran, Laura Mauri

October 13, 2015

Advertisement

Debate: Are We Really Ready for Phase III Trials? For Limb Ischemia There Are Knowns and Unknowns!

Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!

Debate: Are We Really Ready for Phase III Trials? Yes, Mesenchymal Cells Are Ready to Be Tested for Prevention and Treatment of Chronic Ischemic and Nonischemic Heart Failure!

Debate: Are We Really Ready for Phase III Trials? Yes, in STEMI Bone Marrow Mononuclear Fraction Is Ready, and Other Options Are Coming!

Study Shows Initial Aortic Valve Replacement In Asymptomatic Patients With Severe Aortic Stenosis May be Viable Treatment Option

Edwards SAPIEN 3 Valve Demonstrates High Survival And Low Stroke Rate At 1 Year

CE-Approved or EU Studies: JenaValve Technology Review and Clinical Update (JUPITER Trials)

Reversal Agents for Factor Xa Inhibitors

Rivaroxaban: Analysis of Efficacy, Safety, and Special Considerations

Apixaban: Analysis of Efficacy, Safety, and Special Considerations

Dabigatran: Analysis of Efficacy, Safety, and Special Considerations (Including Reversal Agents)

Randomized Trial Of Diabetic Patients In India Finds Paclitaxel-Eluting Stents Failed To Meet Non-Inferiority Compared To Everolimus-Eluting Stents

Polymer-Free Drug-Coated vs. Bare-Metal Coronary Stents In High Bleeding Risk Patients With One Month DAPT

PFO Closure Still Attracts Controversy

MISTRAL-C: Cerebral Protection in TAVR May Reduce New Lesions

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

ISAR-DESIRE 4: Scoring Balloon Predilation Effective at 1 Year in Patients With DES Restenosis

First US Multi-center Study Finds Unprotected TAVR Procedures Produce New Brain Lesions in Nearly All Cases

Drug-Coated Balloon Shown To Be Superior To Conventional Angioplasty In Treating Superficial Femoral Artery Disease After Two Years

Big Data: Opportunities and Challenges 4 Academia Perspectives

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content